Casdin Capital’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Casdin Capital’s Portfolio OMIC Stock Details OMIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-44,129	Closed	-$373K	–	38
2024 Q2	$373K	Sell	44,129 -1	-0%	-$12	0.03%	37
2024 Q1	$681K	Hold	44,130	–	–	0.05%	36
2023 Q4	$609K	Hold	44,130	–	–	0.06%	37
2023 Q3	$504K	Sell	44,130 -727	-2%	-$13.5K	0.06%	38
2023 Q2	$1.12M	Hold	44,857	–	–	0.1%	37
2023 Q1	$1.63M	Hold	44,857	–	–	0.13%	37
2022 Q4	$2.7M	Hold	44,857	–	–	0.21%	42
2022 Q3	$3.36M	Buy	44,857 +16,000	+55%	+$1.67M	0.22%	31
2022 Q2	$3.31M	Sell	28,857 -19,239	-40%	-$2.26M	0.28%	34
2022 Q1	$9.11M	Hold	48,096	–	–	0.41%	37
2021 Q4	$16.7M	Sell	48,096 -41,666	-46%	-$16.2M	0.47%	39
2021 Q3	$30.1M	Hold	89,762	–	–	0.75%	33
2021 Q2	$74M	Buy	+89,762	New	+$69.6M	1.88%	17

Other funds holding OMIC

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

CRCM LP San Francisco, California $141M AUM 153.09% 1-Year Est. Return

QVIDTVM Management The Woodlands, Texas $81.4M AUM 2.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Casdin Capital's OMIC Position: Q3 2024 in Review

Casdin Capital sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q3 2024, closing a stake of 44,129 shares — an estimated $373K sold.

Casdin Capital first reported a position in OMIC in Q2 2021 and held it in 13 quarters. The position peaked at $74M in Q2 2021. 22 funds tracked by Wall St. Rank hold OMIC as of Q3 2024.

Casdin Capital reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Casdin Capital sold 44,129 Singular Genomics Systems, Inc. Common Stock shares in Q3 2024, an estimated $373K.
Casdin Capital first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 13 quarters.
Casdin Capital's Singular Genomics Systems, Inc. Common Stock position peaked at $74M in Q2 2021.
22 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q3 2024.

Based on Casdin Capital's 13F filing for Q3 2024, filed 14 Nov 2024.